Archive | 2021
Irinotecan Plus Doxorubicin Hydrochloride Liposome for Relapsed or Refractory Wilms Tumor
Purpose: The prognosis of the relapsed or refractory Wilms tumor (R/R\nWT) was dismal and new salvage chemotherapy was needed. This study aimed\nto evaluate the efficacy of the combination of irinotecan and\ndoxorubicin hydrochloride liposome regimen (AI) for R/R WT. Methods: The\npresent study enrolled the R/R WT who were treated with AI regimen at\nSun Yat-Sen University Cancer Center from July 2018 to September 2020.\nThe response was defined as the best observed response after the last\ntwo cycle and toxicity was evaluated. Result: Total of 16 patients with\nmedian age of 4.2 years (0.5 to 11 years) were enrolled, including 14\npatients with relapsed disease and 2 patients with refractory disease.\nThese patients received 1 to 8 courses (median 3 courses).14 patients\nwere assessable for response: 2 complete response (CR), 5 partial\nresponse (PR), 2 stable disease (SD), 5 progression disease (PD). The\nobjective response rate was 50% (2 CR, 5 PR) and the disease control\nrate was 64% (2 CR, 5 PR, and 2 SD). The median progression-free\nsurvival was 3.5 months (range 0.5-12 months), and the median survival\nduration was 8 months (range 1-28 months). Sixteen patients were\nassessable for toxicity, with most common grade 3 or 4 adverse events\nwere alopecia (62%), leucopenia (40%), abdominal pain (38%), etc. No\nfatal adverse events have been observed. Conclusion: The AI regimen has\npositive efficacy with tolerated toxicity, it may provide an alternative\noption for the treatment of R/R WT.